SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

Description

This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.

Conditions

Neisseria Gonorrhoeae Infection

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.

Evaluation of SpeeDx's Ciprofloxacin gyrA Assay for Clinical Care of STD Clinic Patients With Neisseria Gonorrhea

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

Condition
Neisseria Gonorrhoeae Infection
Intervention / Treatment

-

Contacts and Locations

Seattle

Public Health -- Seattle & King County Sexual Health Clinic, Seattle, Washington, United States, 98104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * English speaking
  • * Have access to the internet (via computer or phone) on at least a weekly basis
  • * Asymptomatic (as defined below)
  • * Urogenital symptoms consistent with a sexual transmitted infection (other than vaginitis associated with trichomonas vaginalis, bacterial vaginosis or yeast). Symptoms consistent with cervicitis, urethritis, or PID will not be offered enrollment.
  • * Antibiotic use within the last 2 weeks
  • * Contact to syphilis
  • * Contact to an STI and are unwilling to defer empiric treatment until diagnostic test results return
  • * Anyone receiving a gonococcal-active drug (such as Doxycycline, Penicillin, Ceftriaxone) during the visit. Those receiving metronidazole, fluconazole, or clotrimazole will not be excluded.
  • * Known allergy to ciprofloxacin and/or ceftriaxone

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Washington,

Lindley Barbee, MD, MPH, PRINCIPAL_INVESTIGATOR, University of Washington

Study Record Dates

2026-12-31